Company insider dossier

Bio-Techne Corp insider intelligence

TECH filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
49/100

Balanced insider tape

75/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
17 Aug 2026

Investment committee read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 7 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 6 named insiders rather than one filing source.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
  • The latest qualifying filing is more than 30 days old.
Conviction49Balanced insider tape
Confidence75Well supported
Named insiders6participating in the tape
Controlled events26directional common-share events
Acquisition value$9.6Mnormalized amount
Disposal value$17.9Mnormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

72.6165.2657.9250.5743.22 Acquisition · 15 Aug 2026 · Not reportedAcquisition · 15 Aug 2026 · Not reportedAcquisition · 15 Aug 2026 · Not reportedAcquisition · 15 Aug 2026 · Not reportedAcquisition · 15 Aug 2026 · Not reportedAcquisition · 15 Aug 2026 · Not reportedDisposal · 15 Aug 2026 · $783.4KDisposal · 15 Aug 2026 · $312.0KDisposal · 15 Aug 2026 · $143.1KDisposal · 15 Aug 2026 · $141.0KDisposal · 15 Aug 2026 · $97.2KDisposal · 15 Aug 2026 · $15.4KDisposal · 29 Jul 2026 · $3.7MAcquisition · 29 Jul 2026 · $3.0MDisposal · 28 Jul 2026 · $2.1MAcquisition · 28 Jul 2026 · $1.7MDisposal · 23 Jul 2026 · $24.7KAcquisition · 23 Jul 2026 · $21.3KAcquisition · 2 Jun 2026 · Not reportedDisposal · 2 Jun 2026 · $10.8KDisposal · 8 May 2026 · $320.4KAcquisition · 8 May 2026 · $315.9KDisposal · 5 May 2026 · $3.2MAcquisition · 5 May 2026 · $3.0MDisposal · 5 May 2026 · $1.4MAcquisition · 5 May 2026 · $1.3MDisposal · 5 May 2026 · $399.9KAcquisition · 5 May 2026 · $399.8KAcquisition · 1 May 2026 · Not reportedDisposal · 1 May 2026 · $17.1KAcquisition · 22 Apr 2026 · Not reportedAcquisition · 22 Apr 2026 · Not reportedDisposal · 22 Apr 2026 · $3.3MDisposal · 22 Apr 2026 · $79.8KAcquisition · 14 Apr 2026 · Not reportedDisposal · 14 Apr 2026 · $1.9MAcquisition · 3 Apr 2026 · Not reportedDisposal · 3 Apr 2026 · $39.3K
Apr 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
72.61 USD
One-week move
+0.3%
Four-week move
+0.4%
Fair-value gap
+12.8%
Trend signal
Active
Relative strength
3.2

Directional balance

Controlled event mix

26.9%acquisition
Acquisition events
7
Disposal events
19
Net value
-$8.3M

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

006 Jul
013 Jul
320 Jul
627 Jul
003 Aug
4210 Aug
1117 Aug
024 Aug
031 Aug
007 Sep
014 Sep
021 Sep

Named participants

Insider conviction by person

HIPPEL, JAMESCFO556 events
BOHNEN, SHANESVP - General Counsel526 events
KELDERMAN, KIMDirector, Chief Executive Officer507 events
HERR, AMY E.Director463 events
GEIST, WILLIAMPRESIDENT, PROTEIN SCIENCES281 events
CROUSE, STEVEN C.President - Diag & Spatial Bi223 events

Evidence quality

Security and transaction context

Common equity38
Equity compensation44
Options and derivatives10
Other securities0

Role architecture

Who is participating

Other executive41
CEO and chair24
Finance leadership18
Director9

Transaction evidence

Auditable TECH filing ledger

Showing 1 to 30 of 92.

BOHNEN, SHANESVP - General Counsel
AcquisitionEquity compensation
11344 sharesRestricted Stock Units
Not reportedContext evidence
BOHNEN, SHANESVP - General Counsel
AcquisitionEquity compensation
18432 sharesRestricted Stock Units
Not reportedContext evidence
CROUSE, STEVEN C.President - Diag & Spatial Bi
AcquisitionEquity compensation
14140 sharesRestricted Stock Units
Not reportedContext evidence
CROUSE, STEVEN C.President - Diag & Spatial Bi
AcquisitionEquity compensation
8702 sharesRestricted Stock Units
Not reportedContext evidence
GEIST, WILLIAMPRESIDENT, PROTEIN SCIENCES
AcquisitionEquity compensation
14762 sharesRestricted Stock Units
Not reportedContext evidence
GEIST, WILLIAMPRESIDENT, PROTEIN SCIENCES
AcquisitionEquity compensation
23985 sharesRestricted Stock Units
Not reportedContext evidence
HERR, AMY E.Director
AcquisitionEquity compensation
1381 sharesRestricted Stock Units
Not reportedContext evidence
HIPPEL, JAMESCFO
AcquisitionEquity compensation
22438 sharesRestricted Stock Units
Not reportedContext evidence
HIPPEL, JAMESCFO
AcquisitionEquity compensation
36459 sharesRestricted Stock Units
Not reportedContext evidence
KELDERMAN, KIMDirector, Chief Executive Officer
AcquisitionEquity compensation
57590 sharesRestricted Stock Units
Not reportedContext evidence
KELDERMAN, KIMDirector, Chief Executive Officer
AcquisitionEquity compensation
93582 sharesRestricted Stock Units
Not reportedContext evidence
BOHNEN, SHANESVP - General Counsel
DisposalEquity compensation
2332 sharesRestricted Stock Units
Not reportedContext evidence
BOHNEN, SHANESVP - General Counsel
DisposalEquity compensation
49 sharesRestricted Stock Units
Not reportedContext evidence
BOHNEN, SHANESVP - General Counsel
AcquisitionCommon equity
4350 sharesCommon Stock
Not reportedContext evidence
BOHNEN, SHANESVP - General Counsel
DisposalEquity compensation
300 sharesPerformance Restricted Stock Units
Not reportedContext evidence
BOHNEN, SHANESVP - General Counsel
DisposalEquity compensation
4502 sharesPerformance Restricted Stock Units
Not reportedContext evidence
BOHNEN, SHANESVP - General Counsel
DisposalEquity compensation
1669 sharesRestricted Stock Units
Not reportedContext evidence
BOHNEN, SHANESVP - General Counsel
DisposalEquity compensation
12117 sharesPerformance Stock Option (Right to Buy)
Not reportedContext evidence
CROUSE, STEVEN C.President - Diag & Spatial Bi
DisposalEquity compensation
2176 sharesRestricted Stock Units
Not reportedContext evidence
CROUSE, STEVEN C.President - Diag & Spatial Bi
AcquisitionCommon equity
5423 sharesCommon Stock
Not reportedContext evidence
CROUSE, STEVEN C.President - Diag & Spatial Bi
DisposalEquity compensation
1379 sharesRestricted Stock Units
Not reportedContext evidence
CROUSE, STEVEN C.President - Diag & Spatial Bi
DisposalEquity compensation
1868 sharesRestricted Stock Units
Not reportedContext evidence
GEIST, WILLIAMPRESIDENT, PROTEIN SCIENCES
DisposalEquity compensation
567 sharesPerformance Restricted Stock Units
Not reportedContext evidence
GEIST, WILLIAMPRESIDENT, PROTEIN SCIENCES
AcquisitionCommon equity
6416 sharesCommon Stock
Not reportedContext evidence
GEIST, WILLIAMPRESIDENT, PROTEIN SCIENCES
DisposalEquity compensation
8507 sharesPerformance Restricted Stock Units
Not reportedContext evidence
GEIST, WILLIAMPRESIDENT, PROTEIN SCIENCES
DisposalEquity compensation
2623 sharesRestricted Stock Units
Not reportedContext evidence
GEIST, WILLIAMPRESIDENT, PROTEIN SCIENCES
DisposalEquity compensation
3226 sharesRestricted Stock Units
Not reportedContext evidence
GEIST, WILLIAMPRESIDENT, PROTEIN SCIENCES
DisposalEquity compensation
22898 sharesPerformance Stock Options (Right to Buy)
Not reportedContext evidence
HERR, AMY E.Director
AcquisitionCommon equity
589 sharesCommon Stock
Not reportedContext evidence
HERR, AMY E.Director
DisposalEquity compensation
160 sharesRestricted Stock Units
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context